HC Wainwright Reaffirms Buy Rating for Unum Therapeutics (UMRX)

Unum Therapeutics (NASDAQ:UMRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday, March 29th, AnalystRatings.com reports. They currently have a $18.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 400.00% from the company’s current price.

The analysts wrote, “Our price target of $18/share is based on an equally-weighted composite of: (a) $18.1/share, as a 25x multiple of taxed and diluted $7.68 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.7/share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).””

A number of other equities research analysts have also commented on UMRX. Zacks Investment Research lowered shares of Unum Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 21st. Cowen assumed coverage on shares of Unum Therapeutics in a report on Tuesday, February 26th. They set a “market perform” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.60.

UMRX stock traded up $0.04 during midday trading on Friday, reaching $3.60. The company had a trading volume of 63,569 shares, compared to its average volume of 86,913. Unum Therapeutics has a 1 year low of $3.30 and a 1 year high of $17.66. The stock has a market cap of $108.33 million and a PE ratio of -2.59.

Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Unum Therapeutics had a negative net margin of 354.88% and a negative return on equity of 96.46%. The company had revenue of $3.80 million during the quarter, compared to analysts’ expectations of $2.58 million. On average, sell-side analysts forecast that Unum Therapeutics will post -1.3 earnings per share for the current fiscal year.

In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several institutional investors have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. increased its stake in shares of Unum Therapeutics by 7.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock worth $242,000 after acquiring an additional 3,846 shares in the last quarter. American International Group Inc. increased its stake in shares of Unum Therapeutics by 432.8% in the 4th quarter. American International Group Inc. now owns 12,531 shares of the company’s stock worth $55,000 after acquiring an additional 10,179 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Unum Therapeutics by 11.6% in the 4th quarter. Bank of America Corp DE now owns 99,545 shares of the company’s stock worth $438,000 after acquiring an additional 10,317 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Unum Therapeutics in the 3rd quarter worth about $150,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Unum Therapeutics by 2,782.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock worth $213,000 after acquiring an additional 20,033 shares in the last quarter. Institutional investors own 47.46% of the company’s stock.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Further Reading: What are convertible shares? 

Analyst Recommendations for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.